Andrews Paul S, Schneider Steve, Yang Evelyn, Michaels Mark, Chen Hao, Tang Jin, Emkey Renee
Lead Discovery, Amgen Inc., Cambridge, Massachusetts 02142, USA.
Assay Drug Dev Technol. 2010 Aug;8(4):471-87. doi: 10.1089/adt.2009.0264.
The ubiquitin proteasome pathway (UPP) has been implicated in a number of pathogenic diseases: cancer, inflammation, metabolic disorders, and viral infection. The human genome contains well over 500 genes encoding proteins involved in the UPP. Ubiquitin ligases (E3s) comprise the largest subset of these genes, and together with an E2 partner, provide the substrate selectivity required for regulating cellular proteins through the covalent attachment of ubiquitin. Many ligases that have been identified in critical cellular pathways have no known substrates. Even those E3s with known substrates may have a yet unidentified role in the pathways on which they lie and as such may have additional substrates. It is critical to identify these substrates for discovery of selective small molecule inhibitors aimed at therapeutic intervention. Other methods, such as mass spectrometry, have been utilized for identifying ligase substrates, but these are labor-intensive and require a significant investment. In this study, we utilized protein microarrays for the identification of substrates of the HECT domain E3, Smurf1. Smurf1 is a critical regulator of TGF-beta and bone morphogenic protein signaling, and has been demonstrated to play a role in regulating cell polarity through the degradation of RhoA. We set out to identify novel Smurf1 substrates involved in the regulation of the aforementioned pathways. Proof-of-principle experiments with known Smurf1 substrates demonstrated efficient ubiquitination thereby validating this approach. Assaying a human protein microarray for ubiquitination with Smurf1 and the partner E2 ubiquitin ligase Ubch5 or Ubch7 identified 89 potential substrates of the Smurf1 E3 activity, which spanned a number of different biological pathways. Substrates identified utilizing protein microarray technology have been validated in vitro. Here we demonstrate the utility of this approach for identifying substrates of particular E2/E3 complexes.
泛素蛋白酶体途径(UPP)与多种致病疾病有关:癌症、炎症、代谢紊乱和病毒感染。人类基因组包含500多个编码参与UPP的蛋白质的基因。泛素连接酶(E3s)是这些基因中最大的子集,与E2伴侣一起,通过泛素的共价连接提供调节细胞蛋白质所需的底物选择性。在关键细胞途径中已鉴定出的许多连接酶没有已知的底物。即使是那些有已知底物的E3s,在它们所处的途径中可能也有尚未确定的作用,因此可能还有其他底物。识别这些底物对于发现旨在治疗干预的选择性小分子抑制剂至关重要。其他方法,如质谱法,已被用于识别连接酶底物,但这些方法劳动强度大且需要大量投入。在本研究中,我们利用蛋白质微阵列来识别HECT结构域E3,Smurf1的底物。Smurf1是TGF-β和骨形态发生蛋白信号的关键调节因子,并且已被证明通过RhoA的降解在调节细胞极性中发挥作用。我们着手识别参与上述途径调节的新型Smurf1底物。用已知的Smurf1底物进行的原理验证实验证明了有效的泛素化,从而验证了这种方法。用Smurf1和伴侣E2泛素连接酶Ubch5或Ubch7检测人蛋白质微阵列的泛素化,确定了89个Smurf1 E3活性的潜在底物,这些底物跨越了许多不同的生物学途径。利用蛋白质微阵列技术鉴定的底物已在体外得到验证。在这里,我们展示了这种方法在识别特定E2/E3复合物底物方面的实用性。